Treatment practices and perceived challenges for European physicians treating opioid dependence

Heroin Addiction and Related Clinical Problems

Volumn 12, Issue 3, 2010, Pages 9-19

  Bacha, Jamil ^a   Reast, Sue ^b   Pearlstone, Alisa ^a  

^a PCM Scientific   (United Kingdom)

^b Chive Insight and Planning   (United Kingdom)

Author keywords

Buprenorphine; Diversion; Dosing; Induction; Maintenance treatment; Methadone; Misuse; Pharmacotherapy

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG MISUSE; EUROPE; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MEDICAL PRACTICE; OPIATE ADDICTION; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78449309148     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. AITKEN C.K., HIGGS P.G., HELLARD M.E. (2008): Buprenorphine injection in Melbourne, Australia - an update. Drug Alcohol Rev. 27(2): 197-199.
2. ALHO H., SINCLAIR D., VUORI E., HOLOPAINEN A. (2007): Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 88(1): 75-78.
3. BAO Y.P., LIU Z.M., EPSTEIN D.H., DU C., SHI J., LU L. (2009): A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am. J. Drug Alcohol Abuse 35(1): 28-33.
4. BELL J. (2010): The global diversion of pharmaceutical drugs. Addiction 105(9): 1531-1537.
5. BRUGAL M.T., DOMINGO-SALVANY A., PUIG R., BARRIO G., GARCÍA DE OLALLA P., DE LA FUENTE L. (2005): Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 100(7): 981-989.
6. CAPLEHORN J.R., DRUMMER O.H. (1999): Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med. J. Aust. 170(3): 104-109.
7. CONNOCK M., JUAREZ-GARCIA A., JOWETT S., FREW E., LIU Z., TAYLOR R.J., FRY-SMITH A., DAY E., LINTZERIS N., ROBERTS T., BURLS A., TAYLOR R.S. (2007): Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol. Assess. Vol. 11: No. 9.
8. COURTY P. (2003): [High dosage buprenorphine and injection practices. A study of 303 patients]. Ann. Med. Interne (Paris) 154 Spec No 1: S35-S45.
9. DARKE S., WILLIAMSON A., ROSS J., TEESSON M. (2005): Non-fatal heroin overdose, treatment exposure and client characteristics: Findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev. 24: 425-432.
10. DEGENHARDT L., LARANCE B.K., BELL J.R., WINSTOCK A.R., LINTZERIS N., ALI R.L., SCHEUER N., MATTICK R.P. (2009): Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. MJA 191: 161-165.
11. Department of Health (England) and the devolved administrations. (2007): Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive.
12. FERONI I., AUBISSON S., BOUHNIK A.D., PARAPONARIS A., MASUT A., COUDERT C., OBADIA Y. (2005): [Collaboration between general practitioners and pharmacists in the management of patients on high-dosage buprenorphine treatment. Prescribers' practices]. Presse Med. 34(17): 1213-1219.
13. GIBSON A., DEGENHARDT L., MATTICK R.P., ALI R., WHITE J., O'BRIEN S. (2008): Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 103(3): 462-468.
14. GOSSOP M., STEWART D., BROWNE N., MARSDEN J. (2002): Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 97(10): 1259-1267.
15. HOPWOOD M., SOUTHGATE E., KIPPAX S., BAMMER G., ISAAC-TOUA G., MACDONALD M. (2003): The injection of methadone syrup in New South Wales: patterns of use and increased harm after partial banning of injecting equipment. Aust. N.Z. J. Public Health 27(5): 551-555.
16. JENKINSON R.A., CLARK N.C., FRY C.L., DOBBIN M. (2005): Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 100(2): 197-205.
17. JOHNSON R.E., JAFFE J.H., FUDALA P.J. (1992): A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 267(20): 2750-2755.
18. KAKKO J., SVANBORG K.D., KREEK M.J., HEILIG M. (2003): 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebocontrolled trial. Lancet 361(9358): 662-668.
19. KAKKO J., GRÖNBLADH L., SVANBORG K.D., VON WACHENFELDT J., RÜCK C., RAWLINGS B., NILSSON L.H., HEILIG M. (2007): A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am. J. Psychiatry 164(5): 797-803.
20. KARCH S.B., STEPHENS B.G. (2000): Toxicology and pathology of deaths related to methadone: retrospective review. West. J. Med. 172(1): 11-14.
21. KORNØR H., WAAL H., ALI R.L. (2006): Abstinenceorientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug Alcohol Rev. 25(2):123-130. Erratum in: Drug Alcohol Rev. (2009); 28(2): 217.
22. KROOK A.L., BRØRS O., DAHLBERG J., GROUFF K., MAGNUS P., RØYSAMB E., WAAL H. (2002): A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 97(5): 533-542.
23. LAVIGNASSE P., LOWENSTEIN W., BATEL P., CONSTANT M.V., JOURDAIN J.J., KOPP P., REYNAUD-MAURUPT C., RIFF B., VIDEAU B., MUCCHIELLI A. (2002): Economic and social effects of high-dose buprenorphine substitution therapy. Sixmonth results. Ann. Med. Interne (Paris) 153(3 Suppl.): 1S20-S26.
24. LING W., WESSON D.R., CHARUVASTRA C., KLETT C.J. (1996): A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry 53(5): 401-407.
25. LINTZERIS N., CLARK N., WINSTOCK A., DUNLOP A., MUHLEISEN P., GOWING L., ALI R., RITTER A., BELL J., QUIGLEY A., MATTICK R.P., MONHEIT B., WHITE J. (2006): National clinical guidelines and procedures for the use of buprenorphine in the treatment of opioid dependence. Australian Government.
26. LINTZERIS N., LENNÉ M., RITTER A. (1999): Methadone Injecting in Australia: a tale of two cities. Addiction 94(8): 1175-1178.
27. LIU W., CHEN J., RODOLPH M., BEAUCHAMP G., MÂSSE B., WANG S., LI R., RUAN Y., ZHOU F., LEUNG M.K., LAI S., SHAO Y., JACKSON J.B. (2006): HIV prevalence among injection drug users in rural Guangxi China. Addiction 101(10): 1493-1498. Erratum in: Addiction (2007); 102(5): 841.
28. MATTICK R.P., KIMBER J., BREEN C., DAVOLI M. (2002): Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. (4): CD002207.
29. MATTICK R.P., KIMBER J., BREEN C., DAVOLI M. (2004): Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. (3): CD002207
30. MATTICK R.P., KIMBER J., BREEN C., DAVOLI M. (2009): Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence (Review). Cochrane Database Syst. Rev. 4: CD002207.
31. MOSS A.R., VRANIZAN K., GORTER R., BACCHETTI P., WATTERS J., OSMOND D. (1994): HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 8: 223-231.
32. Norwegian Department of Health. (2010): National Guidelines for Medication-Assisted Rehabilitation of Opioid Dependence.
33. OBADIA Y., PERRIN V., FERONI I., VLAHOV D., MOATTI J.P. (2001): Injecting misuse of buprenorphine among French drug users. Addiction 96(2): 267-272.
34. PANI P.P., MAREMMANI I., PIRASTU R., TAGLIAMONTE A., GESSA G.L. (2000): Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 60(1): 39-50.
35. PETITJEAN S., STOHLER R., DÉGLON J.J., LIVOTI S., WALDVOGEL D., UEHLINGER C., LADEWIG D. (2001): Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 62(1):97-104.
36. RIDGE G., GOSSOP M., LINTZERIS N., WITTON J., STRANG J. (2009): Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J. Subst. Abuse Treat. 37(1): 95-100.
37. ROUX P., VILLES V., BRY D., SPIRE B., FERONI I., MARCELLIN F., CARRIERI M.P. (2008): Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France. Addict. Behav. 33(12): 1625-1269.
38. SCHOTTENFELD R.S., PAKES J.R., OLIVETO A., ZIEDONIS D., KOSTEN T.R. (1997): Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatry 54(8): 713-720.
39. STRANG J., SHERIDAN J., HUNT C., KERR B., GERADA C., PRINGLE M. (2005): The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br. J. Gen. Pract. 55(515): 444-451.
40. The College of Physicians of Ontario, Canada. (2005): Methadone Maintenance Guidelines.
41. UNODC and WHO. Principles of drug dependence treatment. Discussion paper; March 2008.
42. US Department Of Health And Human Services; Substance Abuse and Mental Health Services Administration; Center for Substance Abuse Treatment. (2004): Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. A Treatment Improvement Protocol.
43. WU C.H., HENRY J.A. (1990): Deaths of heroin addicts starting on methadone maintenance. Lancet 335(8686): 424.